New antiviral pill could shorten your next cold

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged between 18 to 60 years * Patients with ARVI, including influenza, starting not later than for 1 day prior to inclusion in the study: * The body temperature measured axillary above 37.2 °C * Presence of one of the signs of respiratory disease (runny nose, cough, pain / tickling in the throat) * Presence of one of the systemic symptoms (weakness, myalgia, headache , chills, sweating) * Provide written informed consent * Ability to understand the nature of the study and provide written informed consent in accordance with Good Clinical Practice (GCP) and local law Exclusion Criteria: * Age over 60 years and under 18 years old * Presence of allergic reactions * Intolerance to NSAIDs and iodine-containing drugs * Hypersensitivity to the components of the drug * Mental illness that impedes compliance with the research procedure * Pregnancy or breast-feeding * Presence of acute, clinically significant respiratory and cardio vascular insufficiency, functional disorders of liver, kidney, digestive tract (ulcer disease) determined at physical examination or by laboratory screening tests * Presence of congenital defects or serious chronic disease of the lungs, kidneys, cardiovascular system, nervous system, metabolic disorders, psychiatric disorders, confirmed by patients history or during initial examination * The use of preparations of blood cytokine immunoglobulin in for 3 months prior to the study * Chronic use of alcohol and / or drugs * Presence or history of cancer diseases, HIV, hepatitis B and C * Application of immunosuppressive or immunomodulatory drugs for 6-months prior to the study * Women of child-bearing potential and who do not use acceptable measure of contraception or do not plan to use those throughout the study * Any clinical condition that, according to the investigator, will not allow to safely carry out the protocol and take the studied drugs without risk to health * Patients receiving antiviral therapy, * Participation in other clinical trials at the present time or during the last 3 months.